Invivyd’s (IVVD) Hold Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their hold rating on shares of Invivyd (NASDAQ:IVVD) in a report released on Tuesday, Marketbeat reports.

Several other research firms have also recently weighed in on IVVD. Zacks Research upgraded shares of Invivyd from a “strong sell” rating to a “hold” rating in a research note on Thursday, November 13th. Cantor Fitzgerald began coverage on Invivyd in a research report on Monday, October 6th. They issued an “overweight” rating and a $10.00 price objective for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Invivyd in a report on Friday, October 31st. Finally, HC Wainwright boosted their price objective on Invivyd from $5.00 to $10.00 and gave the company a “buy” rating in a research report on Friday, October 31st. Two research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $7.33.

Invivyd Trading Up 2.6%

Shares of IVVD stock opened at $2.33 on Tuesday. The firm has a market capitalization of $543.17 million, a P/E ratio of -4.96 and a beta of 0.64. Invivyd has a 1 year low of $0.35 and a 1 year high of $3.07. The firm’s fifty day simple moving average is $1.78 and its 200 day simple moving average is $1.16.

Invivyd (NASDAQ:IVVD) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). The company had revenue of $13.13 million during the quarter, compared to the consensus estimate of $12.00 million. Invivyd had a negative net margin of 119.63% and a negative return on equity of 92.97%. Equities research analysts anticipate that Invivyd will post -1.64 EPS for the current fiscal year.

Insider Buying and Selling at Invivyd

In related news, Director Kevin F. Mclaughlin bought 50,000 shares of the company’s stock in a transaction dated Wednesday, November 19th. The stock was acquired at an average cost of $2.50 per share, with a total value of $125,000.00. Following the acquisition, the director owned 50,000 shares in the company, valued at approximately $125,000. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 25.40% of the company’s stock.

Institutional Trading of Invivyd

Several institutional investors have recently bought and sold shares of the stock. XTX Topco Ltd acquired a new position in Invivyd during the first quarter worth $66,000. Invesco Ltd. boosted its stake in shares of Invivyd by 190.6% in the 1st quarter. Invesco Ltd. now owns 108,999 shares of the company’s stock valued at $66,000 after purchasing an additional 71,485 shares in the last quarter. Nuveen LLC bought a new stake in shares of Invivyd in the 1st quarter worth about $65,000. AQR Capital Management LLC increased its position in shares of Invivyd by 2,051.0% during the 1st quarter. AQR Capital Management LLC now owns 410,711 shares of the company’s stock worth $249,000 after purchasing an additional 391,617 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC increased its position in shares of Invivyd by 238.6% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 39,941 shares of the company’s stock worth $29,000 after purchasing an additional 28,146 shares in the last quarter. Institutional investors and hedge funds own 70.36% of the company’s stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.